White Cloud Mountain (00874.HK): CDE agrees to BYS10 patch to conduct phase II single-arm clinical trial application for market launch in the future.

The Zhixun Finance APP reported that Baiyunshan (00874.HK) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., Baiyunshan Pharmaceutical General Factory (hereinafter referred to as "Baiyunshan Pharmaceutical General Factory"), received feedback from the National Drug Administration Center (CDE) on the selective RET small molecule inhibitor BYS10 tablet developed by Baiyunshan Pharmaceutical General Factory.